CIDP

What is CIDP?

CIDP stands for chronic inflammatory demyelinating polyneuropathy. It is a rare, long-lasting condition in which the body’s immune system mistakenly attacks the peripheral nerves. The peripheral nerves are the nerves that lie outside the brain and spinal cord and carry signals to and from the muscles and skin. Each of these nerves is wrapped in a protective coating called myelin, which works a little like the insulation around an electrical wire. In CIDP, inflammation damages this myelin (a process called demyelination), so the nerve signals slow down or fail to arrive. The result is a combination of weakness, numbness, and tingling that develops gradually over weeks or months.

The word chronic distinguishes CIDP from Guillain-Barré syndrome, a related condition in which similar nerve damage appears suddenly and peaks within about four weeks. In CIDP, symptoms typically keep worsening for at least eight weeks, and they may continue in a steadily progressive pattern or come and go in relapses.

CIDP can affect people of any age, including children, but it is most often diagnosed in adults, and it appears to be somewhat more common in men than in women. It is considered an autoimmune condition, meaning the immune system attacks the body’s own tissue. Because CIDP is uncommon and its early signs can resemble many other nerve disorders, it is often diagnosed and managed by a neurologist, a doctor who specializes in the nervous system. At Acibadem, CIDP is evaluated within the Neurology department.

CIDP symptoms

CIDP symptoms usually develop slowly and affect both sides of the body in a roughly symmetrical way. The most typical picture is a combination of muscle weakness and altered sensation that begins in the legs and, in many cases, also involves the arms. Common cidp symptoms include:

• Weakness in the legs and arms, often noticed first as difficulty climbing stairs, rising from a chair, or opening jars
• Numbness or tingling (sometimes called pins and needles), often starting in the feet and hands
• Loss of balance or an unsteady walk, particularly in the dark or when the eyes are closed
• Reduced or absent reflexes, which a doctor notices when tapping the knees or ankles
• Clumsiness with fine hand movements such as buttoning a shirt or writing
• Fatigue that is out of proportion to activity
• Nerve pain, burning, or aching in some people, although pain is less prominent than in some other neuropathies
• Tremor (shaking) of the hands in a minority of people

In its classic form, CIDP affects both the muscles that move the body (motor nerves) and the nerves that carry sensation (sensory nerves), and weakness involves both the muscles close to the body, such as the hips and shoulders, and those farther away, such as the hands and feet. Several less common variants exist. In a purely sensory form, numbness and imbalance dominate and weakness may be minimal. In a purely motor form, weakness occurs without significant sensory changes. In a focal or multifocal form (sometimes called Lewis-Sumner syndrome), symptoms affect individual nerves in an uneven, patchy pattern, often in one arm. In a distal form, symptoms stay mainly in the feet and lower legs.

Symptoms also differ by stage and course. Some people experience a steadily progressive decline, while others have relapses in which symptoms worsen for weeks and then partly or fully improve. Early on, symptoms may be subtle and easily blamed on age, back problems, or diabetes. Later, untreated CIDP can lead to significant disability, including difficulty walking without support. Unlike Guillain-Barré syndrome, CIDP only rarely affects the muscles used for breathing or the nerves of the face, though this can occur.

CIDP causes and risk factors

The exact cidp causes are not fully understood. What is known is that CIDP is an autoimmune disorder: parts of the immune system, including white blood cells and antibodies (proteins that normally target germs), react against components of the myelin sheath and sometimes the underlying nerve fiber. Why this misdirected immune response begins is unclear. Unlike Guillain-Barré syndrome, which often follows an infection, CIDP usually cannot be traced to a single trigger.

In a small proportion of people, specific antibodies directed against proteins at the junction between the myelin and the nerve fiber (the paranode) have been identified. These cases are now often described as autoimmune nodopathies and may behave somewhat differently from typical CIDP, including a poorer response to some standard treatments.

CIDP is not inherited in a simple way, and it is not contagious. Factors that may be associated with a higher chance of developing CIDP or a CIDP-like neuropathy include:

• Older adult age, although the condition can occur at any age
• Male sex
• Diabetes, which appears more often in people with CIDP than would be expected by chance
• Other autoimmune conditions, such as thyroid disease or inflammatory bowel disease
• Certain blood disorders, including abnormal proteins in the blood (monoclonal gammopathy) and some blood cancers
• HIV infection, which is linked to a CIDP-like neuropathy in some people

Some of these are better described as associated conditions than as proven causes. Part of the diagnostic process involves checking for them, because their presence can change how the condition is managed.

CIDP diagnosis

There is no single test that confirms CIDP. A cidp diagnosis rests on the combination of a typical history, findings on physical examination, and supportive results from nerve tests. Neurologists commonly use published diagnostic criteria, such as those from the European Academy of Neurology and the Peripheral Nerve Society, to decide whether the overall picture fits.

The evaluation usually includes several steps:

• Medical history and neurological examination. The doctor asks how symptoms began and progressed, then tests muscle strength, sensation, coordination, and reflexes. Reduced or absent reflexes in the arms and legs are a key clue.
• Nerve conduction studies. Small electrical pulses are applied to a nerve through the skin and the speed and strength of the response are recorded. In CIDP, signals travel more slowly than normal and may be partly blocked, reflecting damaged myelin. This is the most important supporting test.
• Electromyography (EMG). A thin needle electrode records the electrical activity of muscles. It is usually performed together with nerve conduction studies and helps show whether the nerve fibers themselves have been affected.
• Lumbar puncture (spinal tap). A small sample of the fluid that surrounds the spinal cord is removed with a needle in the lower back. In CIDP, the fluid often shows a raised protein level with a normal number of cells, a pattern that supports the diagnosis.
• Blood tests. These are used to look for associated conditions and to rule out other causes of neuropathy, including diabetes, vitamin B12 deficiency, thyroid disease, abnormal blood proteins, and HIV. Testing for specific paranodal antibodies may be requested in selected cases.
• Imaging. Magnetic resonance imaging (MRI) of the spine or nerve roots, or ultrasound of the peripheral nerves, may show thickened or inflamed nerves. Imaging is supportive rather than definitive.
• Nerve biopsy. In a minority of unclear cases, a small piece of nerve, usually from the ankle, is removed and examined under a microscope. This is reserved for situations where other tests have not settled the question, because it leaves permanent numbness in a small area.

Because several other conditions can mimic CIDP, including hereditary neuropathies, neuropathy related to diabetes, and neuropathies caused by abnormal blood proteins, doctors are careful to exclude these before confirming the diagnosis. In some cases the diagnosis is made more confidently in hindsight, when a person responds clearly to treatment.

CIDP treatment options

CIDP is one of the treatable forms of chronic neuropathy. The goals of treatment are to calm the immune attack, allow the myelin to repair, restore strength and sensation as much as possible, and prevent long-term disability. The main cidp treatment options fall into a few groups, and the choice depends on how severe the symptoms are, other medical conditions, and how a person responds over time.

Observation. In people with very mild, stable symptoms that do not interfere with daily life, a neurologist may suggest monitoring without immediate treatment, with regular reviews to catch any worsening early.

Corticosteroids. Steroid medicines such as prednisone or methylprednisolone reduce inflammation and suppress the immune system. They may be given as daily tablets or as high-dose pulses at intervals. Steroids are widely available and inexpensive, but long-term use can cause side effects such as weight gain, high blood sugar, bone thinning, mood changes, and increased risk of infection. Doctors generally aim to use the lowest dose that keeps symptoms controlled and to taper off when possible.

Immunoglobulin therapy. Immunoglobulin is a purified antibody product prepared from donated blood plasma. It can be given into a vein (intravenous immunoglobulin, or IVIG) or under the skin (subcutaneous immunoglobulin, or SCIG). It appears to work by interfering with the harmful immune response. Many people improve within days to weeks of a course, but the effect wears off, so repeated treatments, often every few weeks, are usually needed. Side effects can include headache, chills, and rarely more serious reactions.

Plasma exchange. Also called plasmapheresis, this procedure removes blood through a catheter, separates out the liquid plasma containing harmful antibodies, and returns the blood cells with replacement fluid. It is effective for many people but the benefit is temporary, and it requires specialized equipment and good vein access, so it is typically used when other treatments are not suitable or during severe flares.

Other immune-suppressing medicines. When the first-line treatments do not work well, cause unacceptable side effects, or are needed too often, doctors may add other drugs that dampen the immune system, such as azathioprine, mycophenolate, or rituximab. Evidence for these is more limited than for the first-line options. Rituximab is often considered for people with the paranodal antibodies mentioned above. In 2024, a newer class of medicine that lowers antibody levels by blocking a protein called the neonatal Fc receptor was approved in some countries for CIDP; its role is still being defined.

Surgery. There is no operation that treats CIDP itself. Surgery is not part of standard care, although a nerve biopsy is occasionally used for diagnosis.

Rehabilitation and supportive care. Physical therapy helps maintain strength, flexibility, and balance and reduces the risk of falls. Occupational therapy can suggest adaptations for daily tasks and hand function. Braces, canes, or walkers may be useful during periods of weakness. Nerve pain, when present, may be treated with medicines used for neuropathic pain, such as certain anticonvulsants or antidepressants. Managing associated conditions, particularly diabetes, is also important.

Response to treatment varies. Some people need only a single course and remain well, while others require ongoing therapy for years. Neurologists usually track progress with standardized strength and disability scores and adjust treatment accordingly, including periodic attempts to reduce or pause treatment to see whether the disease has become inactive.

Living with CIDP and outlook

The outlook for CIDP is generally better than for many other chronic nerve conditions because effective treatments exist, but the course is variable and difficult to predict for any individual. In many cases, treatment produces meaningful improvement in strength and function, and a proportion of people eventually achieve remission, meaning the disease becomes inactive with or without ongoing treatment. Others have a relapsing course that requires long-term maintenance therapy, and some experience gradual progression despite treatment.

Earlier diagnosis and treatment are thought to give the best chance of a good recovery, because myelin can repair itself but the underlying nerve fibers, once lost, regenerate slowly and incompletely. People whose nerve tests show substantial fiber loss at diagnosis may recover less fully. Residual symptoms such as fatigue, mild numbness in the feet, or reduced stamina are common even when the disease is controlled.

Living well with CIDP often involves a combination of regular medical follow-up, a consistent exercise program adapted to current strength, attention to foot care and fall prevention because of reduced sensation, and planning for treatment schedules. Fatigue can be a major issue; pacing activities and prioritizing sleep may help. Because several treatments suppress the immune system, staying up to date with recommended vaccinations, following the neurologist’s advice about which vaccines are appropriate, and reporting infections promptly are sensible precautions. Many people find it helpful to connect with patient organizations for peer support and reliable information.

Frequently asked questions

What is CIDP in simple terms?

CIDP is a rare condition in which the immune system attacks the insulating coating of the nerves outside the brain and spinal cord. This slows nerve signals, causing gradual weakness, numbness, and tingling in the arms and legs. It is chronic, meaning it lasts for months or years, but in many cases it can be controlled with treatment.

What are the first cidp symptoms people usually notice?

Early cidp symptoms often include tingling or numbness in the feet, difficulty with stairs or getting up from a chair, unsteadiness when walking, and clumsiness with the hands. Because these changes develop slowly over weeks to months, they are sometimes attributed to other problems at first. A neurological examination that finds reduced reflexes is often the first clue that a nerve disorder is present.

What are the main cidp causes?

CIDP is an autoimmune disorder, but the specific trigger that starts the immune attack is not known in most people. It is not caused by anything a person did, it is not contagious, and it does not usually run in families. Some people have associated conditions such as diabetes, abnormal blood proteins, or specific nerve antibodies, and these are checked for during evaluation.

How is cidp diagnosis confirmed?

There is no single confirmatory test. Doctors combine the history and examination with nerve conduction studies and electromyography, which show slowed or blocked nerve signals typical of myelin damage. A lumbar puncture showing raised protein in the spinal fluid, blood tests to exclude other causes, and sometimes MRI or nerve ultrasound provide supporting evidence. A nerve biopsy is needed only occasionally.

What are the standard cidp treatment options?

The three first-line treatments are corticosteroids, immunoglobulin therapy given into a vein or under the skin, and plasma exchange. They appear to be broadly similar in effectiveness, so the choice depends on a person’s other health conditions, side-effect risks, and practical factors. Other immune-suppressing medicines may be added if these do not work well enough. Physical and occupational therapy support recovery of function.

Can CIDP be cured?

CIDP is not usually described as curable, but it is often treatable, and some people do reach a lasting remission in which the disease becomes inactive and treatment can be stopped. Others need ongoing therapy to keep symptoms under control. The long-term course varies considerably between individuals, so doctors are cautious about predicting outcomes early on.

Is CIDP the same as Guillain-Barré syndrome?

They are related but distinct. Both involve immune damage to the peripheral nerves, but Guillain-Barré syndrome comes on rapidly and reaches its worst point within about four weeks, often after an infection, while CIDP worsens over at least eight weeks and may relapse or progress for years. Treatment approaches overlap, but CIDP frequently requires longer-term therapy.

When to see a doctor

Anyone who notices gradually worsening weakness, numbness, or tingling in the arms or legs, especially on both sides of the body, should arrange a medical evaluation. Slowly developing nerve symptoms are easy to dismiss, but early assessment allows treatable conditions such as CIDP to be identified before permanent nerve damage occurs. People already diagnosed with CIDP should report any new or worsening symptoms to their care team, since adjustments to treatment are often needed.

Seek urgent medical attention if any of the following occur:

• Weakness that progresses rapidly over hours or days rather than weeks
• Shortness of breath, difficulty taking a deep breath, or a weak cough
• Difficulty swallowing, slurred speech, or drooping of the face
• Sudden inability to walk or stand, or repeated falls
• Loss of bladder or bowel control
• Fever, chills, or signs of infection while taking immune-suppressing treatment
• Severe headache, chest pain, or an allergic-type reaction during or after immunoglobulin or plasma exchange treatment

These signs may indicate a severe flare, a different or additional condition, or a treatment complication, and they warrant prompt assessment.